Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition containing human papilloma virus (HPV) plasmodium and immunopotentiator and being used for preventing or treating cervical cancer

A technology of human papillomavirus and immune-enhancing peptides, applied in antiviral agents, viruses/phages, introduction of foreign genetic material using vectors, etc. Significant other issues

Inactive Publication Date: 2016-04-06
GENEXINE CO LTD
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, for the treatment of cervical cancer, in the clinical trials using the composition of the nucleic acid sequence of the E6 and E7 proteins of HPV16, its curative effect is not significant (GarciaFetal. ObstetGynecol2004, 103; 317-326)
This result indicates that the administration of HPV antigen alone is unable to generate an antigen-specific immune response sufficient to treat or suppress cervical cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition containing human papilloma virus (HPV) plasmodium and immunopotentiator and being used for preventing or treating cervical cancer
  • Composition containing human papilloma virus (HPV) plasmodium and immunopotentiator and being used for preventing or treating cervical cancer
  • Composition containing human papilloma virus (HPV) plasmodium and immunopotentiator and being used for preventing or treating cervical cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] Structure of GX-188EDNA

[0064] The definitions of the abbreviations used in the embodiments of the present invention are as follows: optimized nucleic acid sequence, "tPa" or "t" represents the secretion signal sequence of tissue-type plasminogen activator; "F" or "Flt3L" represents the fms-like casein Amino acid kinase 3 ligand.

[0065] The tPa secretion signal sequence comprising the optimized genetic code of the nucleic acid sequence of SEQ ID NO: 5 and the Flt3L comprising the optimized genetic code of the nucleic acid sequence of SEQ ID NO: 6 were chemically synthesized in a linked form. KpnI (5'), NheI (3') sites were added at the end for insertion into the vector. The vector pGX10 for preparing a DNA vaccine (Korean Patent Application Publication No. 2003-0047667) was treated with KpnI and NheI restriction enzymes, and then the synthesized tPa-Flt3L was ligated with ligase to prepare pGX10 / tF.

[0066]The nucleic acid sequence used to encode the optimized...

Embodiment 2

[0067] Confirmation of the therapeutic effect of GX-188E on cervical cancer

[0068] In order to confirm the therapeutic effect of GX-188E on cervical cancer, C57BL / 6 mice were subcutaneously injected with 5×10 5 TC-1 tumor cells were intramuscularly injected with 50 μg and 100 μg of GX-188E on the 3rd and 8th day after injection, and then electroporated. The volume change of tumor cells was observed from the 27th day after the injection of tumor cells, and the spleen of the mice was removed on the 36th day, and then 1×10 6 E6CD8T cell epitope (antigen determinant, epitope) (E6 48-57 ; EVYDFAFRDL, Peptron, Korea) or the E7CD8 T cell epitope of HPV18 (E7 49-57 ; RAHYNIVTF, Peptron, Korea) or the E6 peptide pool (peptidepool) of HPV18 or the E7 peptide pool of HPV18 were placed together on the plate coated with the anti-mouse IFN-g antibody (BDPharmigen, Sandiego, California) of 5 μ g / ml of 50 μl and at 37°C and 5% CO 2 24 hours in an incubator (Froma, Minnesota, USA). A...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a composition containing a human papilloma virus (HPV) plasmodium and an immunopotentiator and being used for preventing or treating cervical cancer. The composition is characterized in that fusion protein is used for treating tumors caused by HPV through inducing HPV 16 and 18 type antigen-specific immune response, wherein the fusion protein comprises fusion polypeptide which is recombined to enable the three dimensional structures of HPV 16 and 18 type antigens E6 and E7 to deform; signal peptide which is used for secreting the fusion polypeptide; immunological enhancement peptide.

Description

technical field [0001] The present invention relates to a composition comprising a human papillomavirus (humanpapillomavirus; HPV) variant and an immune enhancer for preventing or treating cervical cancer. More specifically, the fusion protein treats tumors caused by HPV by inducing HPV16 and 18 antigen-specific immune responses. The fusion protein includes a fusion polypeptide (Polypeptide), a signal peptide and an immune enhancing peptide, and the fusion polypeptide is recombined to deform the three-dimensional structure of antigens E6 and E7 of human papillomavirus types 16 and 18. Background technique [0002] As everyone knows, cervical cancer (cervical cancer) is the disease (zurHausen, Hetal.BiochemBiophysActa1996,1288; F55-F78, MarkHetal.JNatlCancerInst1993,85) caused by the infection of high-risk human papillomaviruses such as human papillomavirus 16 and 18 types ; 958-964). Among the HPV proteins, E6 and E7 proteins play a major role in the pathogenesis of cervic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/62C12N15/63C07K19/00A61K39/12A61P35/00A61P31/20
CPCA61K39/12A61K2039/54A61K2039/545C07K14/005C07K2319/02C12N2710/20021C12N2710/20034Y02A50/30
Inventor 成永喆徐相焕徐裕锡
Owner GENEXINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com